OSTX
OS Therapies IncorporatedOSTX
OSTX
About: OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
Employees: 4
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.77% more ownership
Funds ownership: 0% [Q2] → 0.77% (+0.77%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
381%
upside
Avg. target
$17.50
461%
upside
High target
$20
541%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Jason McCarthy 34% 1-year accuracy 10 / 29 met price target | 381%upside $15 | Buy Maintained | 16 Jan 2025 |
D. Boral Capital Jason Kolbert 39% 1-year accuracy 76 / 193 met price target | 541%upside $20 | Buy Maintained | 15 Jan 2025 |
Financial journalist opinion
Based on 7 articles about OSTX published over the past 30 days
Negative
Seeking Alpha
5 days ago
OS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based Immunotherapy
OSTX's OST-HER2 immunotherapy is in a fully enrolled phase 2b trial for osteosarcoma, which had an updated readout in mid-January 2025. Financially, OSTX has $7.9 million in cash, with recent funding providing a runway until 2026, but remains poorly capitalized and reliant on near-term news. Strengths include a mid-stage product for an unmet need, but risks involve past failures of Listeria-based immunotherapies and uncertain funding prospects.
Positive
Benzinga
6 days ago
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?
On Wednesday, OS Therapies, Inc. OSTX revealed data from a Phase 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.
Neutral
Business Wire
6 days ago
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a Phase 2b clinical trial (NCT04974008) of OST-HER2 (OST31-164) - the Company's HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. The data demonstrate statistically significant res.
Neutral
Business Wire
2 weeks ago
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that its Chair & CEO Paul Romness has accepted an invitation to attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA taking place on January 13-16, 2025 in San Francisco, CA. This premier conference is the largest and most informative health care investment symposium in the i.
Neutral
Business Wire
3 weeks ago
OS Therapies Announces Closing of $6 Million Private Placement
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or the “Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced the closing of a private placement financing, raising approximately $6 million in gross proceeds for the Company, before deducting offering-related expenses. The Company intends to use the proceeds from the private placement for working capital, primarily focused on the clinical and regulatory mil.
Neutral
Business Wire
3 weeks ago
OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, has partnered with B2i Digital to enhance investor outreach. B2i Digital will implement data-driven strategies to raise awareness about OS Therapies' pioneering research and upcoming milestones, including its potentially pivotal Phase 2b clinical trial for OST-HER2 in the rare pediatric orphan disease recurrent, resecte.
Neutral
Business Wire
4 weeks ago
OS Therapies Announces Pricing of $6 Million Private Placement
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has entered into securities purchase agreements with investors to sell 1.5 million units at a price of $4.00 per unit, with each unit consisting of one share of Series A Senior Convertible Preferred Stock (“the Preferred Stock”) initially convertible into one share of common stock and one.
Neutral
Business Wire
2 months ago
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of 2024 ended September 30, 2024 and provided a business update. “The third quarter was pivotal for OS Therapies as we completed our initial public offering and finished dosing the final patient enrolled in our Phase 2b clinical trial of OST-HER2 in resected,.
Neutral
Business Wire
2 months ago
OS Therapies to Present at The Spartan Capital Investor Conference
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at The Spartan Capital Investor Conference. The conference is being held on November 4, 2024 at the Pierre Hotel in New York. The Company's participation aligns with our commi.
Neutral
Business Wire
2 months ago
Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to a webinar on October 30, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature OS Therapies' Chairman and CEO Paul Romness, and Chief Business Officer Gerald Commissiong. They will share insight into the Company's pipeline of novel treatments f.
Charts implemented using Lightweight Charts™